摘要
头颈肿瘤化疗失败的主要原因是多药耐药(MDR),拓扑异构酶Ⅱ(ToPoⅡ)表达异常是引起多药耐药的主要机制之一,称为不典型耐药(at-MDR)。本文就ToPoⅡ的生物学特性、介导at-MDR的机制及以ToPoⅡ为作用靶点的抗肿瘤药物等方面进行综述。
出处
《内蒙古医学院学报》
2005年第6期33-35,共3页
Acta Academiae Medicinae Neimongol
参考文献18
-
1[1]Beauvillain C,Mahe M,Bourdin S,et al.Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced respectable hypopharyngeal carcinomas[J].Laryngoscope,1997;10(7):648-653
-
2[2]Krishnan P,Bastow KF.Novel mechanism of cellular DNA topoisomerase Ⅱ inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone[J].Cancer Chemother Pharmacol,2001 ;47(3):187-198
-
3[4]Tsuruo T.Molecular cancer therapeutics:recent progress and targets in drug resistance[J].Inter Med,2003;42(37):237-243
-
4[5]Malonne H,Atassi G.DNA topisomerase targetin drugs:mechanisms of action and perspectives[J].Anti-Cancer Drugs,1997;8(9):811-822
-
5[6]Cline SD,Macdonald TL,Osheroff N.Azatoxin is a mechanistic hybrid of the topoisomerase Ⅱ-targeted anti-cancer drugs etoposide and ellipticine[J].Biochemistry,1997 ;36(42):13095-13101
-
6[8]Holden JA.DNA topoisomerases as anticancer drug targets:from the laboratory to the clinic[J].Curr Med Chem Anti -canc Agents,2001; 1 (1):1-25
-
7[9]Arbuck SG,Takimoto CH.An overview of topoisomerase 1-targeting agents[J].Seminars in Hematology,1998;35(3):3-14
-
8[10]Drake FH,Hofmann GA,Bartus HF,et al.Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase Ⅱ[J].Biochemistry,1989 ;28(20):8154-8160
-
9[11]Fortune JM,Osheroff N.Merbarone inhibits the catalytic activity of human topoisomerase Ⅱα by blocking DNA cleavage[J].J Biol Chem,1998;273(28):17643-17650
-
10[12]Meng LH,Ding J.Induction of bulk and c-myc P2 promoter specific DNA damage by an antitopoismerase Ⅱ agent salvicine is an early event leading to apoptosis in HL-60 cells[J].FEBS Letter,2001; 501 (1):59-64
同被引文献6
-
1邓刚,杨成章,陈望燕.Ki-67和拓扑异构酶Ⅱα在喉鳞状细胞癌中的表达及意义[J].临床耳鼻咽喉科杂志,2005,19(9):396-398. 被引量：2
-
2Pommier Y,Leteurtre F,Fesen MR. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors[J].Cancer Investigation,1994,(05):530-542.
-
3Horibe Y,Murakami M,Komori K. Expression of topoisomerase Ⅱ alpha,Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation[J].Acta Pathologica,Microbiologica Et Immunologica Scandinavica,2000,(10):689-696.
-
4Shvero J,Koren R,Shvili Ⅰ. Expression of human DNA Topoisomerase Ⅱ-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables[J].American Journal of Clinical Pathology,2008,(06):934-939.doi:10.1309/AJCPROG61USKCBEI.
-
5郭亚青.Mdm2 PARP ToPoⅡ在喉癌中的表达及临床意义[DB]中国优秀硕士学位论文全文数据库,20061-14.
-
6唐平章,王晓雷.中国头颈肿瘤治疗60年巡礼[J].中华耳鼻咽喉头颈外科杂志,2009,44(10):805-807. 被引量：3
-
1虞同华,韩祥.带蒂皮瓣在头颈肿瘤修复中的应用[J].江苏医药,1999,25(8):618-618.
-
2宫丽丽,王民.胸大肌肌皮瓣在头颈部组织缺损修复中的应用[J].中国耳鼻咽喉颅底外科杂志,2006,12(1):64-64. 被引量：7
-
3关文明.老年人饥饿性氮质血症46例误诊分析[J].中国社区医师（医学专业）,2010,12(1):31-31.
-
4张伟,何晓松.STAT3与头颈肿瘤的研究进展[J].临床医学工程,2014,21(2):256-257. 被引量：2
-
5余济春,王弘士.肌瓣、肌皮瓣在头颈肿瘤手术中的应用[J].江西医学院学报,2003,23(5):23-23.
-
6廖立新,潘登,陈刚泉,李莉.拓扑异构酶Ⅰ在人病理性瘢痕组织中的表达分析[J].中国组织工程研究与临床康复,2009,13(37):7291-7295. 被引量：5
-
7李素芳.肌皮瓣移植修复头颈肿瘤切除术后缺损的护理[J].中国实用医药,2014,9(16):199-200.
-
8王昕,宋新丽,李铮,谷清华.泌尿生殖道感染者支原体耐药性分析[J].中华微生物学和免疫学杂志,2002,22(4):455-455. 被引量：94
-
9李赞,周晓,喻建军,陈杰,戴捷,黄文孝,包荣华.游离腹壁下动脉穿支皮瓣在头颈肿瘤术后缺损一期修复的临床应用[J].中国耳鼻咽喉颅底外科杂志,2008,14(1):25-28. 被引量：11
-
10潘登,廖立新.拓扑异构酶Ⅰ在病理性瘢痕组织中的表达[J].实用临床医学（江西）,2008,9(5):18-19.
